CRIS Current Research Information System

ZAMAGNI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 12.631
NA - Nord America 11.692
EU - Europa 7.886
SA - Sud America 747
AF - Africa 653
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 5
Totale 33.641
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.456
CN - Cina 3.456
SG - Singapore 3.182
VN - Vietnam 3.130
IT - Italia 2.162
GB - Regno Unito 1.491
DE - Germania 892
SE - Svezia 769
HK - Hong Kong 740
BR - Brasile 534
FR - Francia 524
IN - India 511
KR - Corea 433
BD - Bangladesh 402
NL - Olanda 381
RU - Federazione Russa 371
IE - Irlanda 262
UA - Ucraina 221
FI - Finlandia 219
JP - Giappone 203
CI - Costa d'Avorio 188
ZA - Sudafrica 156
CA - Canada 118
EE - Estonia 101
TG - Togo 101
SC - Seychelles 99
AR - Argentina 96
PH - Filippine 87
AT - Austria 77
BG - Bulgaria 70
CH - Svizzera 69
TH - Thailandia 68
MX - Messico 59
ES - Italia 58
ID - Indonesia 57
BE - Belgio 50
PL - Polonia 47
TR - Turchia 47
IQ - Iraq 45
JO - Giordania 45
EC - Ecuador 35
TW - Taiwan 33
SA - Arabia Saudita 28
EG - Egitto 24
AU - Australia 23
CZ - Repubblica Ceca 23
IR - Iran 23
CO - Colombia 22
GR - Grecia 22
PK - Pakistan 22
NG - Nigeria 21
CL - Cile 18
UZ - Uzbekistan 16
LB - Libano 15
MA - Marocco 15
MY - Malesia 15
IL - Israele 14
GT - Guatemala 12
VE - Venezuela 12
KE - Kenya 11
LT - Lituania 11
RO - Romania 11
TN - Tunisia 11
PY - Paraguay 9
UY - Uruguay 9
DO - Repubblica Dominicana 8
AL - Albania 7
DZ - Algeria 7
JM - Giamaica 7
KZ - Kazakistan 7
NP - Nepal 7
OM - Oman 7
PT - Portogallo 7
AZ - Azerbaigian 6
HR - Croazia 6
PE - Perù 6
RS - Serbia 6
AE - Emirati Arabi Uniti 5
CY - Cipro 5
ET - Etiopia 5
HN - Honduras 5
NO - Norvegia 5
TT - Trinidad e Tobago 5
BO - Bolivia 4
CR - Costa Rica 4
HU - Ungheria 4
KG - Kirghizistan 4
LV - Lettonia 4
QA - Qatar 4
BZ - Belize 3
GH - Ghana 3
MK - Macedonia 3
NI - Nicaragua 3
PR - Porto Rico 3
SN - Senegal 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BY - Bielorussia 2
GE - Georgia 2
Totale 33.596
Salva come PNG Salva come JPEG
Città #
Singapore 2.231
Ashburn 1.369
Southend 1.229
Fairfield 1.030
Hefei 908
Chandler 841
Ho Chi Minh City 719
Hong Kong 707
Hanoi 612
San Jose 559
Woodbridge 483
Seattle 451
Bologna 441
Wilmington 412
Houston 408
Dallas 405
Seoul 393
Beijing 386
Cambridge 351
Ann Arbor 345
Princeton 310
Santa Clara 310
Dong Ket 286
Dublin 258
New York 256
Boardman 255
Los Angeles 220
Lauterbourg 210
Abidjan 188
Milan 171
Tokyo 167
Council Bluffs 159
Helsinki 159
Jacksonville 122
Nanjing 121
Westminster 113
Buffalo 108
Haiphong 108
Berlin 103
Padova 103
Lomé 101
Frankfurt am Main 92
Bengaluru 88
São Paulo 85
Bremen 81
Da Nang 81
Munich 78
Jinan 76
Turin 76
Guangzhou 74
Rome 72
San Diego 71
Shanghai 70
Sofia 68
Redondo Beach 64
Tianjin 63
Chicago 62
Shenyang 61
Saint Petersburg 60
Hyderabad 58
Changsha 56
Florence 51
Redwood City 51
Amsterdam 49
Brussels 46
Amman 45
Redmond 44
Lappeenranta 43
Nuremberg 43
Vienna 42
Zhengzhou 42
Nanchang 41
Shenzhen 41
London 40
Bern 39
Johannesburg 38
Toronto 38
Can Tho 37
Naples 37
Jakarta 36
Phoenix 36
Falls Church 33
Hangzhou 33
Hải Dương 33
Hebei 32
Biên Hòa 31
Orem 31
San Francisco 31
Warsaw 31
Falkenstein 30
Paris 30
Atlanta 28
Wuhan 28
Des Moines 27
Fabriano 27
Medford 27
Washington 27
Brooklyn 26
Jiaxing 26
Mexico City 26
Totale 20.940
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 711
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 349
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 320
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 311
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 270
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 251
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 249
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 247
A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM 239
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 236
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 235
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 233
A new risk stratification model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 patients collected by European Myeloma Network Within HARMONY Big Data Platform 232
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 230
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 224
The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. 222
Assessmen of disease ativity in multiple myeloma with FDG-PET imaging 221
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 219
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 216
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 215
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 214
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 211
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 211
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 210
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 210
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 209
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 209
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 208
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 208
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 205
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 204
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 204
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 203
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 202
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 202
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 201
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 200
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 200
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 199
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 198
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 197
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 197
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 197
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. 196
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 195
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 195
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 195
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 193
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 190
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 189
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 189
Contrast enhanced MRI and (18)F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease 189
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia 188
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 187
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 186
Thalidomide maintenance in multiple myeloma: certainties and controversies. 184
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 184
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. 181
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 180
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 179
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 178
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 178
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 178
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 177
Oxytocin Modulates Osteogenic Commitment in Human Adipose-Derived Stem Cells 176
Dermoscopy of cutaneous involvement by multiple myeloma 176
Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma 176
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 175
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 175
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 174
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells 172
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 172
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 171
Comparison between 18F-FDG PET/CT and 11C-Choline PET/CT for the evaluation of multiple myeloma 168
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 167
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 166
The role of imaging techniques in the management of multiple myeloma 166
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 166
Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report 166
Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel 165
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 164
18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. 164
IMWG consensus on risk stratification in multiple myeloma. 164
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 163
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 163
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project 162
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 162
Oxytocin modulates osteogenic commitment in human adipose-derived mesenchymal stem cells 161
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 160
Report of the 6th International Workshop on PET in lymphoma 160
Extramedullary disease in multiple myeloma: a systematic literature review 158
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 158
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature 157
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 156
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma 155
Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. 155
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 155
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 155
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group 155
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 155
Totale 19.953
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.131
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.131
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021683 0 0 0 0 0 0 0 0 0 0 0 683
2021/20222.916 250 124 186 206 274 142 82 220 139 242 550 501
2022/20233.506 352 533 161 514 230 285 112 194 554 135 265 171
2023/20241.323 83 182 97 100 116 264 77 127 34 93 84 66
2024/20255.039 209 568 422 411 522 266 429 170 135 505 403 999
2025/202614.596 1.253 1.886 1.358 1.062 1.323 736 1.212 503 2.553 1.129 968 613
Totale 34.401